魯抗醫藥(600789.SH):擬配股募資不超10億元 用於製劑新產品產業化建設項目等
格隆匯11月30日丨魯抗醫藥(600789.SH)公佈2021年度配股公開發行證券預案,公司此次公開發行證券擬採用向原股東配售股份的方式進行。
此次配股的股份數量以實施此次配股方案的A股股權登記日收市後的A股股份總數為基數確定,按每10股配售不超過3股的比例向全體股東配售。配售股份不足1股的,按上海證券交易所及中國證券登記結算有限責任公司上海分公司的有關規定處理。
若以截至2021年9月30日公司總股本880,260,920股為基礎測算,此次可配股數量為不超過2.64億股。
此次配股募集資金總額不超過10億元,扣除發行費用後的募集資金淨額用於製劑新產品產業化建設項目、高端原料藥多功能發酵車間及配套動力建設項目(一期)、新藥研發項目和補充流動資金及償還銀行貸款。此次配股募集資金具體投向如下:

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.